Conference
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
Authors
Daud A; Blank CU; Robert C; Puzanov I; Richtig E; Margolin KA; O'Day S; Nyakas M; Lutzky J; Tarhini AA
Volume
34
Pagination
pp. 9513-9513
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2016
DOI
10.1200/jco.2016.34.15_suppl.9513
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X